tbuckley/cabot-search huggingface dataset:
Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease
Authors: Hongtao Liu, Greg Koval, Greg Malnassy, Pamela Ihonor, Hui Liu, Roger Luo, Amittha Wickrema, Steven Dowdy, Michael Thirman, Koen van Besien, Wendy Stock
Journal: Blood (2010)
STMC-34. ROLE OF INTERLEUKIN-8/CXCR2 REGULATED EPIGENETIC PLASTICITY IN GBM RECURRENCE
Authors: Tanwir Hasan, Fatemeh Atashi, Janice Kim, Donna Guo, Cheol Park, Meijing Wu, Mahua Dey, Maciej Lesniak, Craig Horbinski, Atique Ahmed
Journal: Neuro-Oncology (2016)

Emerging evidence has revealed the enrichment of cancer stem cells (CSCs) in glioblastoma (GBM) and other cancers post-therapy. This can occur by dedifferentiation of non-CSCs to CSCs within the tumor population, which may be responsible for promoting the therapeutic resistance. To elucidate the molecular mechanisms of post-therapy cellular plasticity, a gene expression analysis, comparing the pre- and the post-therapy GBM CSCs (GSCs), revealed that Interleukin-8 (IL-8) transcripts are significantly elevated in post-therapy CD133+ GSCs. IL-8 is a pro-inflammatory chemokine that is upregulated both at mRNA and protein level upon therapeutic stress. The IL8 cognate receptor CXCR2 positive non-GSC population converts to CD133+ GSCs during chemotherapy. Exposure to IL8 significantly enhanced the self-renewing capacity of PDX GBMs (average 3-fold, p<0.0005), and shRNA-mediated knockdown of IL8 significantly delayed PDX GBM tumor growth in vivo (p<0.0005). Analysis of the Cancer Genome Atlas data demonstrated that IL8 transcript expression is negatively correlated with GBM patient survival (p=0.001). Gene expression analysis in different anatomic regions of GBM, in the Ivy Glioblastoma Atlas Project, indicates that IL8 expression is positively correlated with stemness genes such as CD133 and SOX2 within pseudopalisading cells around necrotic areas, and also in the leading edge region within patient GBM (p<0005, r=0.7; p=0.03, r=0.48). In sicilo analysis indicates that IL8 may regulate Polycomb Repressor Complex 2 (PRC2) activity and experimental data showed that IL8/CXCR2 signaling induces phosphorylation of the PRC2 complex catalytic subunit enhancer of zeste 2 (EZH2), and promotes epigenetic plasticity in chemotherapy-treated GBM PDX. Together, these results suggest that IL-8/CXCR2 signaling can promote post therapy stemness by inducing epigenetic plasticity in GBM.
GENT-24. LONG NON-CODING RNA CRNDE AS A POTENTIAL EGFR-REGULATED ONCOGENE IN GLIOMA
Authors: Gilberto Leung, Xiao-qin Zhang
Journal: Neuro-Oncology (2016)

Long non-coding RNAs (lncRNAs) have recently been shown to play important roles in glioma development and progression. However, information on their functions and molecular mechanisms remains limited. Colorectal Neoplasia Differentially Expressed (CRNDE) is a novel lncRNA that has been found to be significantly upregulated in gliomas relative to normal brain tissues, and positively correlated with tumor grading. In the present study, we investigated the prognostic value of CRNDE and its underlying molecular mechanism in glioma. Based on two independent publicly accessible cohorts of glioblastoma multiforme patients treated with an uniform regimen, high CRNDE level was found to be associated with significantly poorer overall survival. Functional assays using three glioblastoma cell lines revealed that CRNDE knock-down could significantly inhibit glioma cell growth, increase cell apoptosis, induce cell cycle arrest at G0/G1 phase, and impair cell invasion. Further in vivo studies using a subcutaneous xenograft rodent model showed that cells with downregulated CRNDE expression exhibited significantly slower growth rate. We also identified a significant association between CRNDE expression and EGFR signaling in vitro. CRNDE expression was more abundant in EGFR-mutant samples than in EGFR-wild cases. Activation of EGFR signaling by EGF or inhibition by an EGFR-tyrosine kinase inhibitor in cell lines would enhance or suppress CRNDE expression, respectively. These findings suggest that CRNDE may potentially be under positive regulation by EGFR signaling, and may play a significant oncogenic role in glioma pathogenesis. CRNDE should be further explored as a potential biomarker and therapeutic target in glioma.
Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell Transplantation (SCT).
Authors: Marcie Tomblyn, Jeffrey S. Miller, Linda J. Burns, Bruce R. Blazar, Mukta Arora, Xianghua Luo, Todd Defor, Claudio Brunstein, Kathryn Dusenbery, Margaret L. MacMillan, Michael Verneris, John Wagner, Daniel J. Weisdorf
Journal: Blood (2006)
Interrupted 131I Procedures for Patients With Differentiated Thyroid Cancer
Authors: Shawn Karls, Gad Abikhzer, Michael Tamilia, Stephan Probst
Journal: Clinical Nuclear Medicine (2017)

In patients with differentiated thyroid carcinoma scheduled to receive doses of I for diagnostic or therapeutic purposes, we compared patients prepared with thyroid hormone withdrawal (THW) versus recombinant human thyroid stimulating hormone (rh-TSH) to evaluate the incidence of cancelled procedures because of inadequate thyroid stimulation.Thyroid cancer patients after thyroidectomy who were scheduled for diagnostic or therapeutic I procedures between January 2012 and June 2015 were retrospectively reviewed. Patients were divided based on preparation modality (THW vs rh-TSH), and the incidence of cancelled procedures was compared.Charts from 761 patients were reviewed, 292 THW and 569 rh-TSH. A total of 10 patients (3.4%) in the THW group had cancelled procedures because of insufficient thyroid stimulation (TSH < 20 mU/L). If a TSH threshold of 30 mU/L were used, 57 patients (17.1%) would have been cancelled. Comparing the groups with chi-squared analysis for both TSH thresholds yielded significantly more cancellations in the THW group (P < 0.001).Our study has shown that THW in preparation for I procedures leads to significantly more cancellations because of insufficient thyroid stimulation as compared with rh-TSH, which led to no cancellations. The added cost and inconvenience to this cancer population should therefore be considered when selecting a preparation modality.Retrospective cohort-Level III.
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
Authors: T. Petrella, C. Copie-Bergman, J. Brière, R. Delarue, F. Jardin, P. Ruminy, C. Thieblemont, M. Figeac, D. Canioni, P. Feugier, B. Fabiani, K. Leroy, M. Parrens, M. André, C. Haioun, G.A. Salles, P. Gaulard, H. Tilly, J.P. Jais, T.J. Molina
Journal: Annals of Oncology (2017)
Safety and efficacy of first-line XELIRI with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies.
Authors: P. Garcia-Alfonso, S. Alvarez, A. Munoz, P. Lopez, C. Riesco, J. Adeva, M. Martin
Journal: Journal of Clinical Oncology (2011)

560 Background: The safety and efficacy of first-line XELIRI (capecitabine in combination with irinotecan) and XELIRI plus bevacizumab (BEV) have been evaluated in patients with metastatic colorectal cancer (mCRC). To date, however, no randomized studies comparing these regimens have been performed. This retrospective analysis compared efficacy and safety data for the two regimens from separate phase II studies performed at a single institution. Methods: Patients with histologically documented metastatic or recurrent CRC and no prior treatment for advanced disease received irinotecan 175 mg/m 2 on day 1 and oral capecitabine 1,000 mg/m 2 twice daily on days 2-8 every 2 weeks (XELIRI study). For patients age ≥65 years, the starting doses of irinotecan and capecitabine were reduced to 140 mg/m 2 and 750 mg/m 2 , respectively. In the second study, patients received the same regimen plus BEV 5 mg/kg on day 1 (XELIRI + BEV study). Results: A total of 53 and 46 patients were entered into the XELIRI and XELIRI + BEV studies, respectively. Patient characteristics were generally similar in both groups. Efficacy results for the ITT populations are summarized in the Table. Patients treated with XELIRI + BEV had a significantly higher ORR and longer median TTP vs. XELIRI alone and a numerically longer median OS was observed (p=NS). The overall incidence of adverse events (all grades or grade 3/4) was similar in the two groups, although alopecia, mucositis, hand–foot syndrome, and haemorrhage were more common with XELIRI + BEV vs. XELIRI alone (all p&lt;0.05). Conclusions: In this retrospective comparison of two studies, the addition of BEV to XELIRI appeared to improve outcome relative to XELIRI alone in the first-line treatment of patients with mCRC. The overall incidence of adverse events was similar in the two groups. [Table: see text] No significant financial relationships to disclose.
Disparities of incidence and survival in lung cancer: A SEER-based analysis on Asians living in the United States from 1973 to 2007.
Authors: R. N. Rahman, S. Rastogi, A. M. Hossain
Journal: Journal of Clinical Oncology (2011)

1572 Background: Asian population living in the US (US-ASN) comprises 4% of total US population. It is a rapidly growing minority group. Lung cancer (LC) is the second most common cancer in US-ASN reported in SEER (Surveillance, Epidemiology and End Result) database from 1973-2007. This is the first study reporting disparities of incidence and survival of LC in US-ASN. Methods: Since 1973, SEER has been reporting data on US-ASN as separate ethnic group. Using the SEER database including patients diagnosed with LC from 1973-2007, we performed frequency & rate analysis on demographics, incidence and treatment, comparing US-ASN, Caucasian (USW), Hispanic, and African-American (AA). Multivariate analyses and survival sessions (Kaplan-Meier, age-adjusted) were also performed. Results: LC accounts about 13% (28,325) of all cancers (213,512) in US-ASN reported in SEER; is more common in male (64% vs. 36%, p < 0.0001) with incidence rate of 41 per 100,000 (less common than USW and AA, p < 0.001). LC is the fifth leading cancer in Asia according to 2010 WHO's data. Median age of diagnosis is significantly less in US-ASN (62 vs. 71 yrs, p < 0.0001), more patients less than 50 years of age at diagnosis (21% vs. 11%, p < 0.0001) with advanced stages (p < 0.001) and grades (p < 0.001) in comparison to other major US ethnicities. But overall, stage and gender specific 1-5 year survival is significantly better (p < 0.01 – 0.02) in US-ASN than other ethnicities. Cox regression analysis showed that age at diagnosis, stages, grades, marital status, and yearof diagnosis were predictors of death. Relative risk of death increased with higher grades, stages and older ages. Conclusions: This is the first study analyzing the epidemiological and survival data of US-ASN with LC. US-ASN change their demographics of LC with migration. It shows clearly and identifies some unique age, stage and biological features of LC in US-ASN. The difference in age of diagnosis and survival are intriguing. It could be due to differences in access to care, tumor biology or other factors. This study has potential implication in screening and therapeutic recommendation in US-ASN population.
Quality and Safety in Health Care, Part XXIV
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2017)

The use of registries such as the Vascular Quality Initiative and its regional groups, such as the Vascular Study Group of New England, have been very helpful in investigating problems related to quality and safety in vascular surgery. This article discusses some of their contributions regarding carotid artery procedures, the use of certain medications in the perioperative period, and the risk factors for sustaining a major cardiac complication while in the hospital after vascular surgery.
Transdermal granisetron for the prevention of chemotherapy-induced nausea and vomiting in metastatic colorectal cancer patients with high risk of bowel obstruction treated with temozolomide
Authors: M.A. Calegari, S. Monterisi, A. Orlandi, A. Inno, R. Barile, S. Corallo, C. Di Dio, V. Zurlo, M. Basso, A. Cassano, C. Barone
Journal: Annals of Oncology (2016)
The Oxidant Response Transcription Factor NRF2 Mediates Heme Activation of Placenta Growth Factor Expression in Erythroid Cells, a Contributor to Pulmonary Hypertension in Sickle Cell Disease
Authors: Maria G Kapetanaki, Deva Sharma, Oluwabukola T Gbotosho, Valerie Schrott, Frances Weidart, Solomon Fiifi Ofori-Acquah, Grant C Bullock, Gregory J. Kato
Journal: Blood (2015)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
Authors: G. Rinnerthaler, S.P. Gampenrieder, D. Voskova, A. Petzer, M. Hubalek, E. Petru, B. Hartmann, J. Andel, M. Balic, T. Melchardt, B. Mlineritsch, R. Greil
Journal: Annals of Oncology (2016)
Erratum: Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
Authors: M M Patnaik, E A Wassie, E Padron, F Onida, R Itzykson, T L Lasho, O Kosmider, C M Finke, C A Hanson, R P Ketterling, R Komrokji, A Tefferi, E Solary
Journal: Blood Cancer Journal (2015)

Correction to: Blood Cancer Journal (2015) 4, e270; doi:10.1038/bcj.2014.90; published online 2 January 2015 Since publication, the publishers have identified that this article was incorrectly placed in volume 4. The article belongs in volume 5. The publishers would like to apologise for any inconvenience caused.
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma
Authors: James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons, Wael Harb, Hesham Mohamed, Ali Nourbakhsh, Robert Rifkin
Journal: American Journal of Hematology (2017)

Abstract Elotuzumab, an immunostimulatory SLAMF7‐targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3‐h infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade 1/2: 29; Grade 3: 4). This phase 2 study (NCT02159365) investigated an accelerated infusion schedule in 70 patients with newly diagnosed multiple myeloma or RRMM. The primary endpoint was cumulative incidence of Grade 3/4 IRs by completion of treatment Cycle 2. Dosing comprised elotuzumab 10 mg/kg intravenously (weekly, Cycles 1‐2; biweekly, Cycles 3+), lenalidomide 25 mg (daily, Days 1‐21), and dexamethasone (28 mg orally and 8 mg intravenously, weekly, Cycles 1‐2; 40 mg orally, weekly, Cycles 3+), in 28‐day cycles. Premedication with diphenhydramine, acetaminophen, and ranitidine (or their equivalents) was given as in previous studies. If no IRs occurred, infusion rate was increased in Cycle 1 from 0.5 to 2 mL/min during dose 1 (∼2 h 50 min duration) to 5 mL/min for the entire infusion by dose 3 and also during all subsequent infusions (∼1‐h duration). Median number of treatment cycles was six. No Grade 3/4 IRs occurred; only one Grade 1 and one Grade 2 IR occurred, both during the first infusion. These data support the safety of a faster infusion of elotuzumab administered over ∼1 h by the third dose, providing a more convenient alternative dosing option for patients.
Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC
Authors: N. Boeckx, A. Toler, K. Op de Beeck, G. Kafatos, V. Deschoolmeester, C. Rolfo, K. Lowe, G. Van Camp, G. Demonty, M. Peeters
Journal: Annals of Oncology (2016)
Cardiopulmonary Functional Status in Children with SCD at Baseline: Pulse Pressure As a Biomarker of Early Compromise
Authors: Caterina P. Minniti, Gregory J. Kato, Mehdi Nouraie, Shoaib Alam, Andrew Campbell, Sohail R. Rana, Deepika Darbari, Oswaldo L Castro, Victor R. Gordeuk
Journal: Blood (2014)
Prolactin Receptor–Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity
Authors: Karthik M. Sundaram, Yilin Zhang, Anirban K. Mitra, Jean-Louis K. Kouadio, Katja Gwin, Anthony A. Kossiakoff, Brian B. Roman, Ernst Lengyel, Joseph A. Piccirilli
Journal: Cancer Research (2017)

Poor prognosis of ovarian cancer, the deadliest of the gynecologic malignancies, reflects major limitations associated with detection and diagnosis. Current methods lack high sensitivity to detect small tumors and high specificity to distinguish malignant from benign tissue, both impeding diagnosis of early and metastatic cancer stages and leading to costly and invasive surgeries. Tissue microarray analysis revealed that >98% of ovarian cancers express the prolactin receptor (PRLR), forming the basis of a new molecular imaging strategy. We fused human placental lactogen (hPL), a specific and tight binding PRLR ligand, to magnetic resonance imaging (gadolinium) and near-infrared fluorescence imaging agents. Both in tissue culture and in mouse models, these imaging bioconjugates underwent selective internalization into ovarian cancer cells via PRLR-mediated endocytosis. Compared with current clinical MRI techniques, this targeted approach yielded both enhanced signal-to-noise ratio from accumulation of signal via selective internalization and improved specificity conferred by PRLR upregulation in malignant ovarian cancer. These features endow PRLR-targeted imaging with the potential to transform ovarian cancer detection. Cancer Res; 77(7); 1684-96. ©2017 AACR.
Prognostic implications of baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in metastatic gastric cancer (GC) patients
Authors: A. Petrillo, M.M. Laterza, J. Ventriglia, B. Savastano, G. Tirino, L. Pompella, E. Martinelli, F. Morgillo, M. Orditura, F. Ciardiello, F. De Vita
Journal: Annals of Oncology (2016)
LOH as “the missing instability” potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer
Authors: M. Bersanelli, L. Gnetti, C. Azzoni, L. Bottarelli, D. Gasparro, F. Leonardi, E.M. Silini, S. Buti
Journal: Annals of Oncology (2016)
Independent Validation of Effect of <i>HSD3B1</i> Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer
Authors: Neeraj Agarwal, Andrew W. Hahn, David M. Gill, James M. Farnham, Austin I. Poole, Lisa Cannon-Albright
Journal: JAMA Oncology (2017)

found by Hearn et al (9.8 months).One limitation of the present study is that PFS was determined by PSA progression alone in most patients because imaging studies were not consistently performed in this real world population.Conclusions | In this study, we independently validate that the HSD3B1 (1245C) variant allele is associated with a shorter PFS on ADT in men with mHSPC, and we confirm that the allele frequency of HSD3B1 is about 30% in this population.The 10% of men homozygous for variant allele HSD3B1 (1245C) are likely to have suboptimal response to ADT alone.These men may benefit more from up-front docetaxel treatment or from enrollment in trials investigating up-front deeper androgen blockade with novel androgen-signaling inhibitors.
A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Authors: J.L. Derks, R.J. van Suylen, E. Thunnissen, M.A. Den Bakker, H. Groen, E.F. Smit, R.A. Damhuis, E.-J. Speel, A.-M.C. Dingemans
Journal: Annals of Oncology (2016)
Exome Sequencing and Ultra-Deep Sequencing of Paired Diagnosis, Remission and Relapse Samples Reveals the Clonal Diversity and Treatment-Induced Evolution of Childhood Acute Lymphoblastic Leukemia
Authors: Roland P. Kuiper, Simon V. van Reijmersdal, Marc M Hahn, Edwin Sonneveld, Peter M. Hoogerbrugge, Ad Geurts van Kessel
Journal: Blood (2012)
Crucial Factors of the Inflammatory Microenvironment Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating Survival and Inhibiting Proliferation of CD34+ stem/Progenitor Cells
Authors: Lucia Catani, Lara Rossi, Daria Sollazzo, Eugenia Franchini, Marco Romano, Elisa Zuffa, Martina Barone, Margherita Perricone, Nicola Polverelli, Emanuela Ottaviani, Giovanni Martinelli, Nicola Vianelli, Francesca Palandri
Journal: Blood (2014)
QLIF-04. MEASURING MOBILITY AND DISABILITY IN PATIENTS WITH GLIOMAS
Authors: Shiao-Pei Weathers, Elizabeth Vera Bolanos, Samuel Payen, Alvina Acquaye, Amy Ng, Jeffrey Weinberg, Paul Brown, Terri Armstrong
Journal: Neuro-Oncology (2016)

Patients with gliomas experience high symptom burden that can result in severe neurologic and physical dysfunction. The purpose of this study was to describe the utility and feasibility of established objective measures of mobility and disability, the Timed Up and Go (TUG) and Timed Sit to Stand (TSS) tests. Primary brain tumor patients undergoing routine care performed the TUG and TSS tests and self-reported symptom burden and interference using the MDASI-BT. Clinical and demographic characteristics were collected from the medical chart. Feasibility was assessed by completion rates and time. Relationships between completion time and clinical characteristics were explored with Mann-Whitney tests and Spearman’s rho correlations. Completion times were also compared to community dwelling adults. Of the 43 patients enrolled (mean age: 47, 56% male), 42 and 41 completed the TUG and TSS tests respectively. Older patients and those with poor KPS took more time to complete the TUG (r = 0.578; U=26, p<0.01) and TSS (r = 0.497; U=79.5, p<0.01). Worse self-reported activity-related interference was associated with longer completion times, TUG (r = 0.758), TSS (r = 0.653). A nonsignificant trend was found with longer completion times on both measures based on tumor grade, recurrence, and current treatment status. When compared to older community dwelling adults, glioma patients in this study took more time to complete both function tests with results indicating a high risk for falling. The TUG and TSS tests are feasible for primary brain tumor patients and may aid in clinical care by assessing patient safety and fall risk. Older patients, poor performance status, and higher self-reported activity related interference were associated with greater impairment. Continued data collection will further assess the potential impact of treatment, symptom interference and tumor characteristics on these functional measures to understand the risks throughout the illness trajectory.
Sharp shoulder pain, getting worse, after a fall
Authors: Lauren Ramsay
Journal: BMJ (2017)

A 62 year old man saw his general practitioner with worsening shoulder pain after a minor fall. The GP requested a radiograph. On the basis of the radiograph alone (fig 1⇓), what imaging would you request next?



Fig 1  Anteroposterior plain radiograph of the right shoulder



Computed tomography (CT) of the chest and upper abdomen. The shoulder radiograph shows a cavitating lung nodule measuring approximately 2 cm (fig 2⇓). This is most likely a primary lung carcinoma and should be investigated with referral …